Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

27.18 +1.56 (+6.09%)
Official Closing Price Updated: 7:00 PM EDT, May 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 97,521,568
Open 26.33
Bid (Size) 27.21 (1)
Ask (Size) 27.22 (1)
Prev. Close 25.62
Today's Range 26.02 - 27.45
52wk Range 25.20 - 40.36
Shares Outstanding 5,606,688,356
Dividend Yield 6.03%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Pfizer (PFE) Q1 2024 Earnings Call Transcript
PFE earnings call for the period ending March 31, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Why Pfizer Stock Blasted More Than 6% Higher Today
A double beat on earnings, plus raised bottom-line guidance, made the company a hot item on Hump Day. 
Via The Motley Fool

Performance

YTD
-8.58%
-8.58%
1 Month
-1.95%
-1.95%
3 Month
+0.37%
+0.37%
6 Month
-10.91%
-10.91%
1 Year
-30.41%
-30.41%

More News

Read More
Dow Jumps 200 Points Following Fed Decision; Pfizer Earnings Top Estimates
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
PFE Stock Earnings: Pfizer Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Pfizer Q1 Earnings and Revenues Beat Estimates
Via Talk Markets
Pfizer Embraces Direct-To-Consumer Model For Covid Antiviral, Says Comirnaty Revenues Continue To Perform Consistently With Expectations
Via Benzinga
Exposures COVID-19
(PFE) - Analyzing Pfizer's Short Interest
Via Benzinga
US Stocks Mixed Ahead Of Fed Meeting, Chipmakers Tumble After AMD Earnings, Bitcoin Sinks: What's Driving Markets Wednesday?
Via Benzinga
Topics Economy
Exposures Interest Rates
GSK Sees Strong Demand For Vaccines and Asthma Drugs, Raises Annual Outlook
Via Benzinga
Pfizer Jumps After Raising Its Outlook On The Heels Of A Big Quarterly Beat
Via Investor's Business Daily
Pfizer Reports First-Quarter 2024 Results
From Pfizer Inc.
Via Business Wire
Wall Street Set To Open Lower After AMD Earnings Disappoint As Traders Look To Fed's Powell For Relief: Why This Analyst Sees Incoming Summer Rally
Via Benzinga
Topics Economy
Exposures Interest Rates
Investor Sentiment Falls, Dow Snaps Five-Month Win Streak
Via Benzinga
Topics Stocks
Exposures US Equities
Amazon, Pfizer And 3 Stocks To Watch Heading Into Wednesday
Via Benzinga
7 Safe Haven Stocks That Can Withstand the Market’s Worst Meltdowns
Via InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Pfizer Sees Less Revenue From Covid-19 Treatments, Stock Faces Headwinds Ahead Of Q1 Earnings
Via Benzinga
Exposures COVID-19
5 Top Stocks to Buy in May
Via The Motley Fool
Why I'm Buying This Beaten-Down, High-Yield Dividend Stock Hand Over Fist
Via The Motley Fool
Forget Nvidia: Prominent Billionaires Are Selling It and Buying These 2 Ultra-High-Yield Dividend Stocks Instead
Via The Motley Fool
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer
From Genmab A/S
Via Business Wire
FDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical Cancer
From Pfizer Inc.
Via Business Wire
mRNA Is Promising A Breakthrough In Fighting Cancer
Via Benzinga
Exposures COVID-19
3 Beaten-Down Stocks I Wouldn't Touch With a 10-Foot Pole
Via The Motley Fool
Pfizer Highlights Progress in Accelerating Breakthrough Cancer Medicines at ASCO 2024 Annual Meeting
From Pfizer Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.